fda compounded tirzepatide Judge says compounding pharmacies must stop making copies of Zepbound, Mounjaro FDA says 'no clinical need'

(2024), published in Nature Medicine's SELECT analysis, reported that semaglutide enabled users to achieve a lower body mass index (BMI)

A composite analysis of 8 cardiovascular outcomes trials completed in 2021 demonstrated reduced incidence of major cardiovascular events by 14% and cardiovascular death by 13% (NCT01147250, NCT01179048, NCT01720446, NCT01144338, NCT02465515, NCT01394952, NCT02692716, NCT03496298)

revealed the incorporation of 13 C label from labelled acetyl-l-carnitine into glutamate and GABA neurotransmitters, suggesting that acetyl-l-carnitine was used as a substrate for their biosynthesis [25]

Furthermore, its short half-life of less than 3 h (Min et al., 2025) necessitates twice-daily injections to maintain efficacy, which can be a limiting factor for long-term patient adherence

The lead researcher Mahmoud Nassar, M.D., Ph.D., from the Division of Endocrinology, Diabetes, and Metabolism in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in Buffalo, N.Y., mentioned that doctors have been careful when prescribing these medications to patients with a history of pancreatitis because of the potential risk of exacerbating the condition

Some women with PCOS see improved fertility from GLP-1 medications